Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
BörsenkürzelACON
Name des UnternehmensAclarion Inc
IPO-datumApr 22, 2022
CEONess (Brent)
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeApr 22
Addresse8181 Arista Place
StadtBROOMFIELD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl80021
Telefon18332752266
Websitehttps://aclarion.com/
BörsenkürzelACON
IPO-datumApr 22, 2022
CEONess (Brent)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten